Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2025-03-19
2025-09-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Fruit/Vegetable Drinks on the Human Intestine
NCT02377063
Study of the Effect of a Fermented Dairy Product on Gastrointestinal Well Being in Adult Women
NCT01388010
Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID
NCT06560554
Effect of Spice Consumption on the Microbiome
NCT03676803
Effects of Kimchi Supplementation on Gut Microbiota, DNA Methylation and Serum Proteomes
NCT05917392
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This research will expand the limited existing literature on the effect of fermented vegetable intake on LAB abundance, GI symptoms, fecal consistency and frequency.
Specific knowledge will be produced regarding the magnitude and variation in the increase in LAB bacterial load during fermented vegetable consumption and whether one week is sufficient for LAB to pass out of the gastrointestinal tract. The effect of fermented vegetable consumption on total salivary sIgA levels in healthy adults will also be determined.
The study will also produce knowledge on whether symptoms of bloating and flatulence will improve with fermented vegetables. Stool consistency, stool frequency, GI symptoms, blood pressure and product acceptability data will inform the study design for a future randomized controlled trial of the effects of fermented vegetables on gut microbiome composition and function, gut health and immune function.
The impacts of fermented vegetable consumption on the human gut microbiome, intestinal permeability, and GI inflammation will also be determined with in vitro experiments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fermented vegetable consumption
Participants will complete a 1-week baseline with no fermented food intake, followed by a 4-day fermented vegetable intervention, and then a 1-week follow-up period with no fermented food intake.
Fermented vegetable intervention
Participants will be provided with reduced-sodium fermented vegetables developed by Dr. Ilenys Pérez-Díaz at the USDA-ARS Food Science and Market Quality and Handling Research Unit. The fermented, refrigerated vegetables have been shown to have Lactiplantibacillus spp. content \>10\^7 CFU/mL at 21 days shelf-life.
Products are prepared in a Good Manufacturing Practices Facility at North Carolina State University, Department of Food, Bioprocessing, and Nutrition Sciences.
The fermented vegetables will be shipped in coolers on cold packs with temperature indicators to the WHNRC. Participants will be asked to consume two pre-packaged 50g servings of fermented vegetables a day, for a total daily serving of 100g, not to heat the fermented vegetables prior to consumption, to log their consumption and to rate the acceptability of the fermented vegetables. They will be advised to avoid other fermented foods and to otherwise maintain their habitual diet.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fermented vegetable intervention
Participants will be provided with reduced-sodium fermented vegetables developed by Dr. Ilenys Pérez-Díaz at the USDA-ARS Food Science and Market Quality and Handling Research Unit. The fermented, refrigerated vegetables have been shown to have Lactiplantibacillus spp. content \>10\^7 CFU/mL at 21 days shelf-life.
Products are prepared in a Good Manufacturing Practices Facility at North Carolina State University, Department of Food, Bioprocessing, and Nutrition Sciences.
The fermented vegetables will be shipped in coolers on cold packs with temperature indicators to the WHNRC. Participants will be asked to consume two pre-packaged 50g servings of fermented vegetables a day, for a total daily serving of 100g, not to heat the fermented vegetables prior to consumption, to log their consumption and to rate the acceptability of the fermented vegetables. They will be advised to avoid other fermented foods and to otherwise maintain their habitual diet.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI 18.5 - 39.9 kg/m2
Exclusion Criteria
* BMI less than 18.5 or greater than 39.9
* Pregnant or breastfeeding
* Allergy or sensitivity to any fruit or vegetable
* Dietary restriction preventing consumption of fermented vegetables
* Consumption of probiotic supplements, foods or drinks in the past month
* Probiotic supplements include any tablets, liquids, powders, chewables or other formulations that provide high-quantity, live probiotic microbes
* Probiotic foods and drinks include products labeled as 'probiotic' because they contain live microbes in types and quantities that may confer a health benefit
* Regular consumption, defined as consumption more than once per week in the past two weeks, of live microbe-containing fermented vegetables or cultured dairy products, such as kimchi, refrigerated fermented pickles, traditional (lacto-fermented) sauerkraut, yogurt, or kefir
* In case of less frequent consumption, defer study start such that baseline assessments are completed at least two weeks after last intake
* Unwillingness to abstain from non-study fermented foods and probiotics during the trial
* Uncomfortable with or unwilling to complete stool sample or saliva collections
* Current participation in another interventional research study
* Having fewer than 3 bowel movements per week
* Unmanaged hypertension, defined as blood pressure greater than or equal to 140/90 mmHg
* Current diagnosis of:
* Disease that affects the immune system or causes immune impairment, including HIV/AIDS
* Cancer
* Diabetes
* Asthma with daily medication
* Primary immune deficiency
* Auto-immune disease
* Chronic gastrointestinal disorder (e.g. Crohn's disease, irritable bowel syndrome, colitis, gastric ulcer)
* Chronic kidney disease
* Current use for 2 weeks or longer of:
* Any drug that affects the immune system, such as immunosuppressants, immune modifying drugs, or corticosteroids (e.g. cortisone, prednisone, methylprednisolone)
* Biologics (e.g. Lantus, Remicade, Rituxan, Humira, Herceptin, Avastin, Lucentis, Enbrel)
* GLP-1 agonists, such as semaglutide and tirzepatide.
* Antidiabetic medications, such as Metformin.
* Diuretics, such as Hydrochlorothiazide
* Use of sulfonamides or antimicrobials, including antibiotics, antifungals, antivirals, and antiparasitic medications in the past 3 months
* Use of laxatives in the past 2 weeks
* Currently undergoing cancer treatment with radiation or drugs
* History of gastrointestinal surgery that would impact study outcomes, such as gastric bypass, intestinal resection, surgeries of the liver or pancreas, or removal of part or all of any organ of the GI tract
* Having within the past 2 weeks:
* Diarrheal illness, defined as passing 3 or more abnormally loose or watery stools in a 24-hour period
* Persistent vomiting
* Fever
* Having within the past 3 months:
* Surgery
* Hospitalization
* Having within the past 1 month:
* Colonoscopy
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
USDA, Western Human Nutrition Research Center
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bess L Caswell
Research Nutritionist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Danielle G Lemay, PhD
Role: PRINCIPAL_INVESTIGATOR
USDA, Western Human Nutrition Research Center
Bess L Caswell, PhD
Role: PRINCIPAL_INVESTIGATOR
USDA, Western Human Nutrition Research Center
Mary E Kable, PhD
Role: PRINCIPAL_INVESTIGATOR
USDA, Western Human Nutrition Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
USDA Western Human Nutrition Research Center
Davis, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USDA 2032-10700-002-000D
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
FL125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.